Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens
To assess the efficacy of two inactivated vaccines against Avibacterium paragallinarum serovar B variant infection in laying hens, day-old female chicks were allocated into five experimental groups (G): G1 received a commercial vaccine V1, strains 17756, 0222, and Modesto of serotypes A, B, and C, r...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artículo |
| Language: | Inglés |
| Published: |
American Association of Avian Pathologists
2025
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.12123/23472 https://meridian.allenpress.com/avian-diseases/article-abstract/doi/10.1637/aviandiseases-D-25-00017/507630/Efficacy-of-Different-Vaccination-Plans-Against?redirectedFrom=fulltext https://doi.org/10.1637/aviandiseases-D-25-00017 |
| _version_ | 1855487136490323968 |
|---|---|
| author | Huberman, Yosef Daniel Mendez, Laura Luján Mendez, Maria Alejandra Lomonaco, Jorgelina Gulle, Abel Horacio Gulle, Cristian Horacio De Soler Pinart, M. Baratelli, B. Criado, B. Dardi, M. Ponti, M. |
| author_browse | Baratelli, B. Criado, B. Dardi, M. De Soler Pinart, M. Gulle, Abel Horacio Gulle, Cristian Horacio Huberman, Yosef Daniel Lomonaco, Jorgelina Mendez, Laura Luján Mendez, Maria Alejandra Ponti, M. |
| author_facet | Huberman, Yosef Daniel Mendez, Laura Luján Mendez, Maria Alejandra Lomonaco, Jorgelina Gulle, Abel Horacio Gulle, Cristian Horacio De Soler Pinart, M. Baratelli, B. Criado, B. Dardi, M. Ponti, M. |
| author_sort | Huberman, Yosef Daniel |
| collection | INTA Digital |
| description | To assess the efficacy of two inactivated vaccines against Avibacterium paragallinarum serovar B variant infection in laying hens, day-old female chicks were allocated into five experimental groups (G): G1 received a commercial vaccine V1, strains 17756, 0222, and Modesto of serotypes A, B, and C, respectively, at 8 and 12 wk of life; G2 received V1 through an early vaccination plan at 5 and 12 wk of life; G3 received another commercial vaccine V2, strains 083, Spross, 48, and H18 of serotypes A, B, Bvar, and C, respectively, against infectious coryza, which contained a serovar B variant strain in its formulation at 8 and 12 wk of life. Chickens in G4 were not vaccinated and challenged and were used as positive control, and G5 was not vaccinated and not challenged and served as negative control. At 25 wk of life, chickens from G1 to G4 were inoculated (by injection into the infraorbital sinus) with the serovar B variant of Av. paragallinarum, strain INTA H8, into the left infraorbital sinus of each animal. Clinical signs were monitored daily until Day 5 postchallenge. On that day, bacterial isolation was performed on both inoculated and noninoculated sinuses from each animal to determine the presence of Av. paragallinarum. The interpretation of clinical signs involved grading on a scale from 0 to 4, depending on the severity of conjunctivitis and swelling of the periorbital area. On Day 2 postchallenge, the highest number of birds from all inoculated groups exhibiting clinical signs was recorded, gradually decreasing over the following days. The unvaccinated group (G4) had significantly (χ2, P < 0.05) more birds with clinical signs compared to vaccinated birds, regardless of the immunization plan or age. Overall, no significant differences were observed between G1 and G3 on any of the postchallenge observation days. However, G1 had significantly fewer birds exhibiting clinical signs compared to G2, the group that received the early vaccination plan. On the other hand, comparing the results of the noninoculated sinuses, no differences were found among vaccinated birds in G1, G2, and G3, whereas significantly more infected sinuses were found in the nonvaccinated birds. In conclusion, both V1 and V2 demonstrated efficacy in significantly reducing clinical signs, both with the conventional vaccination plan at 8 and 12 wk of life (V1 and V2) as well as with early vaccination starting at 5 wk of age (V1), compared to nonvaccinated birds. It also showed effectiveness in reducing the presence of Av. paragallinarum in the infraorbital sinuses following the experimental challenge with the serovar B variant. Furthermore, V1, which does not have a Bvar strain, was proven to be effective against the serovar B variant of Av. paragallinarum, specifically demonstrating its efficacy in protecting against clinical signs associated with this particular serovar. |
| format | Artículo |
| id | INTA23472 |
| institution | Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina) |
| language | Inglés |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | American Association of Avian Pathologists |
| publisherStr | American Association of Avian Pathologists |
| record_format | dspace |
| spelling | INTA234722025-08-19T13:47:34Z Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens Huberman, Yosef Daniel Mendez, Laura Luján Mendez, Maria Alejandra Lomonaco, Jorgelina Gulle, Abel Horacio Gulle, Cristian Horacio De Soler Pinart, M. Baratelli, B. Criado, B. Dardi, M. Ponti, M. Coriza Vacuna Inactivada Avibacterium paragallinarum Infección Experimental Ganilla Ponedora Vacunación Argentina Coryza Inactivated Vaccines Experimental Infection Layer Chickens Vaccination To assess the efficacy of two inactivated vaccines against Avibacterium paragallinarum serovar B variant infection in laying hens, day-old female chicks were allocated into five experimental groups (G): G1 received a commercial vaccine V1, strains 17756, 0222, and Modesto of serotypes A, B, and C, respectively, at 8 and 12 wk of life; G2 received V1 through an early vaccination plan at 5 and 12 wk of life; G3 received another commercial vaccine V2, strains 083, Spross, 48, and H18 of serotypes A, B, Bvar, and C, respectively, against infectious coryza, which contained a serovar B variant strain in its formulation at 8 and 12 wk of life. Chickens in G4 were not vaccinated and challenged and were used as positive control, and G5 was not vaccinated and not challenged and served as negative control. At 25 wk of life, chickens from G1 to G4 were inoculated (by injection into the infraorbital sinus) with the serovar B variant of Av. paragallinarum, strain INTA H8, into the left infraorbital sinus of each animal. Clinical signs were monitored daily until Day 5 postchallenge. On that day, bacterial isolation was performed on both inoculated and noninoculated sinuses from each animal to determine the presence of Av. paragallinarum. The interpretation of clinical signs involved grading on a scale from 0 to 4, depending on the severity of conjunctivitis and swelling of the periorbital area. On Day 2 postchallenge, the highest number of birds from all inoculated groups exhibiting clinical signs was recorded, gradually decreasing over the following days. The unvaccinated group (G4) had significantly (χ2, P < 0.05) more birds with clinical signs compared to vaccinated birds, regardless of the immunization plan or age. Overall, no significant differences were observed between G1 and G3 on any of the postchallenge observation days. However, G1 had significantly fewer birds exhibiting clinical signs compared to G2, the group that received the early vaccination plan. On the other hand, comparing the results of the noninoculated sinuses, no differences were found among vaccinated birds in G1, G2, and G3, whereas significantly more infected sinuses were found in the nonvaccinated birds. In conclusion, both V1 and V2 demonstrated efficacy in significantly reducing clinical signs, both with the conventional vaccination plan at 8 and 12 wk of life (V1 and V2) as well as with early vaccination starting at 5 wk of age (V1), compared to nonvaccinated birds. It also showed effectiveness in reducing the presence of Av. paragallinarum in the infraorbital sinuses following the experimental challenge with the serovar B variant. Furthermore, V1, which does not have a Bvar strain, was proven to be effective against the serovar B variant of Av. paragallinarum, specifically demonstrating its efficacy in protecting against clinical signs associated with this particular serovar. Eficacia de diferentes planes de vacunación contra la infección experimental con una variante de la serovariedad B de Avibacterium paragallinarum en gallinas de postura en Argentina. Para evaluar la eficacia de dos vacunas inactivadas contra la infección por la variante del serotipo B de Avibacterium paragallinarum en gallinas de postura, se asignaron pollitas de un día de edad a cinco grupos experimentales (G): el grupo G1 recibió la vacuna comercial V1, cepas 17756, 0222 y Modesto de los serotipos A, B y C, respectivamente, a las 8 y 12 semanas de vida; el grupo G2 recibió la V1 mediante un plan de vacunación temprana a las 5 y 12 semanas de vida; el grupo G3 recibió otra vacuna comercial V2, cepas 083, Spross, 48 y H18 de los serotipos A, B, Bvar y C, respectivamente, contra la coriza infecciosa, que contenía una cepa variante de la serovariedad B en su formulación a las 8 y 12 semanas de vida. Los pollos en el grupo G4 no fueron vacunados ni desafiados y se utilizaron como control positivo, y el grupo G5 no fue vacunado ni desafiado y sirvió como control negativo. A las 25 semanas de vida, los pollos de los grupos G1 al G4 fueron inoculados (por inyección en el seno infraorbitario) con la variante de la serovariedad B de A. paragallinarum, cepa INTA H8, en el seno infraorbitario izquierdo de cada animal. Los signos clínicos se monitorearon diariamente hasta el día 5 después del desafío. Ese día, se realizó el aislamiento bacteriano en los senos inoculados y no inoculados de cada animal para determinar la presencia de A. paragallinarum. La interpretación de los signos clínicos implicó una calificación en una escala de 0 a 4, dependiendo de la severidad de la conjuntivitis y la inflamación del área periorbitaria. En el día 2 después del desafío, se registró el mayor número de aves de todos los grupos inoculados que exhibieron signos clínicos, disminuyendo gradualmente durante los días siguientes. El grupo no vacunado (G4) tuvo significativamente (v2 , P , 0,05) más aves con signos clínicos en comparación con las aves vacunadas, independientemente del plan de inmunización o de la edad. En general, no se observaron diferencias significativas entre los grupos G1 y G3 en ninguno de los días de observación posteriores al desafío. Sin embargo, el grupo G1 tuvo significativamente menos aves que exhibieron signos clínicos en comparación con el grupo G2, el grupo que recibió el plan de vacunación temprana. Por otro lado, comparando los resultados de los senos paranasales no inoculados, no se encontraron diferencias entre las aves vacunadas en los grupos G1, G2 y G3, mientras que se encontraron significativamente más senos paranasales infectados en las aves no vacunadas. En conclusión, tanto V1 como V2 demostraron eficacia en la reducción significativa de los signos clínicos, tanto con el plan de vacunación convencional a las 8 y 12 semanas de vida (V1 y V2), como con la vacunación temprana a partir de las 5 semanas de edad (V1), en comparación con aves no vacunadas. También mostraron eficacia en la reducción de la presencia de A. paragallinarum en los senos infraorbitales tras la exposición experimental a la variante de la serovariedad B. Además, V1, que no contiene una cepa Bvar, demostró ser eficaz contra la variante de la serovariedad B de A. paragallinarum, demostrando específicamente su eficacia en la protección contra los signos clínicos asociados a esta serovariedad en particular. EEA Balcarce Fil: Huberman, Yosef Daniel. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: Méndez, Laura. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: Méndez, Alejandra. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: Lomónaco, Jorgelina. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: Gulle, Abel. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: Gulle, Cristian. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Balcarce; Argentina Fil: De Soler Pinart, M. Hipra Scientific; España Fil: Baratelli, B. Hipra Scientific; España Fil: Criado, B. Hipra Scientific; España Fil: Dardi,M. Hipra Scientific; España Fil: Ponti, M. Hipra Scientific; España 2025-08-19T13:20:02Z 2025-08-19T13:20:02Z 2025-08 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/23472 https://meridian.allenpress.com/avian-diseases/article-abstract/doi/10.1637/aviandiseases-D-25-00017/507630/Efficacy-of-Different-Vaccination-Plans-Against?redirectedFrom=fulltext 1938-4351 (online) 0005-2086 (print) https://doi.org/10.1637/aviandiseases-D-25-00017 eng info:eu-repograntAgreement/INTA/2019-PD-E5-I103-001, Desarrollo de tecnologías diagnósticas y estudios epidemiológicos para el control de enfermedades que afectan la producción animal y la salud pública info:eu-repograntAgreement/INTA/2023-PE-L01-I022, Desarrollo sustentable de la avicultura pampeana info:eu-repo/semantics/restrictedAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) application/pdf American Association of Avian Pathologists Avian Diseases : 1-7 (2025) |
| spellingShingle | Coriza Vacuna Inactivada Avibacterium paragallinarum Infección Experimental Ganilla Ponedora Vacunación Argentina Coryza Inactivated Vaccines Experimental Infection Layer Chickens Vaccination Huberman, Yosef Daniel Mendez, Laura Luján Mendez, Maria Alejandra Lomonaco, Jorgelina Gulle, Abel Horacio Gulle, Cristian Horacio De Soler Pinart, M. Baratelli, B. Criado, B. Dardi, M. Ponti, M. Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens |
| title | Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens |
| title_full | Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens |
| title_fullStr | Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens |
| title_full_unstemmed | Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens |
| title_short | Efficacy of Different Vaccination Plans Against Experimental Infection with a Serovar B Variant of Avibacterium paragallinarum from Argentina in Laying Hens |
| title_sort | efficacy of different vaccination plans against experimental infection with a serovar b variant of avibacterium paragallinarum from argentina in laying hens |
| topic | Coriza Vacuna Inactivada Avibacterium paragallinarum Infección Experimental Ganilla Ponedora Vacunación Argentina Coryza Inactivated Vaccines Experimental Infection Layer Chickens Vaccination |
| url | http://hdl.handle.net/20.500.12123/23472 https://meridian.allenpress.com/avian-diseases/article-abstract/doi/10.1637/aviandiseases-D-25-00017/507630/Efficacy-of-Different-Vaccination-Plans-Against?redirectedFrom=fulltext https://doi.org/10.1637/aviandiseases-D-25-00017 |
| work_keys_str_mv | AT hubermanyosefdaniel efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT mendezlauralujan efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT mendezmariaalejandra efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT lomonacojorgelina efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT gulleabelhoracio efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT gullecristianhoracio efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT desolerpinartm efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT baratellib efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT criadob efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT dardim efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens AT pontim efficacyofdifferentvaccinationplansagainstexperimentalinfectionwithaserovarbvariantofavibacteriumparagallinarumfromargentinainlayinghens |